Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 12:47 | 2026-03-27 | LENZ | LENZ Therapeutics, Inc. | George Jeffrey P. | Director | Biological Products, (No Diagnostic Substances) | BUY | $8.92 | 5,592 | $49,890 | 5,592 | +100.0% |
| 2026-03-27 20:05 | 2026-03-26 | IBIO | iBio, Inc. | Banjak Marc | Officer; Chief Legal Officer | Pharmaceutical Preparations | BUY | $1.65 | 13,934 | $23,055 | 25,000 | +125.9% |
| 2026-03-28 00:06 | 2026-03-25 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer; President, R&D | Pharmaceutical Preparations | OPT+S | $20.11 | 12,000 | $241,320 | 112,622 | -9.6% |
| 2026-03-28 00:15 | 2026-03-27 | ANAB | ANAPTYSBIO, INC | Faga Daniel | Director, Officer; President, CEO | Pharmaceutical Preparations | SALE | $61.61 | 17,679 | $1,089,198 | 495,965 | -3.4% |
| 2026-03-28 00:00 | 2026-03-25 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | SALE | $85.00 | 2,000 | $170,000 | 179,371 | -1.1% |
| 2026-03-27 23:33 | 2026-03-26 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $104.24 | 24,765 | $2,581,504 | 60,753 | -29.0% |
| 2026-03-27 23:34 | 2026-03-26 | PTGX | Protagonist Therapeutics, Inc | SELICK HAROLD E | Director | Pharmaceutical Preparations | OPT+S | $105.00 | 24,000 | $2,520,000 | 60,845 | -28.3% |
| 2026-03-27 23:36 | 2026-03-26 | PTGX | Protagonist Therapeutics, Inc | MOLINA ARTURO MD | Officer; Chief Medical Officer | Pharmaceutical Preparations | OPT+S | $104.79 | 15,000 | $1,571,850 | 84,115 | -15.1% |
| 2026-03-27 22:17 | 2026-03-26 | CNTA | Centessa Pharmaceuticals plc | Anderson Karen M. | Officer; Chief People Officer | Pharmaceutical Preparations | OPT+S | $30.12 | 41,076 | $1,237,382 | 62,085 | -39.8% |
| 2026-03-27 21:50 | 2026-03-25 | KALV | KalVista Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners III, L.P. | 10% owner | Pharmaceutical Preparations | SALE | $17.20 | 214,631 | $3,691,138 | 5,089,354 | -4.0% |
| 2026-03-27 20:57 | 2026-03-25 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Officer; CHIEF MEDICAL OFFICER | Pharmaceutical Preparations | OPT+S | $35.10 | 40,000 | $1,404,024 | 25,000 | -61.5% |
| 2026-03-27 20:44 | 2026-03-25 | TYRA | Tyra Biosciences, Inc. | KAPLAN GILLA | Director | Pharmaceutical Preparations | OPT+S | $36.97 | 14,295 | $528,506 | 28,231 | -33.6% |
| 2026-03-27 20:25 | 2026-03-25 | LEGN | Legend Biotech Corp | Huang Ying | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $8.77 | 9,936 | $87,139 | 247,438 | -3.9% |
| 2026-03-27 20:27 | 2026-03-25 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $50.07 | 26,198 | $1,311,826 | 2,918,326 | -0.9% |
| 2026-03-27 20:31 | 2026-03-26 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer; CFO AND TREASURER | Pharmaceutical Preparations | OPT+S | $535.90 | 10,000 | $5,359,005 | 18,876 | -34.6% |
| 2026-03-27 20:32 | 2026-03-26 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $535.81 | 9,500 | $5,090,216 | 40,513 | -19.0% |
| 2026-03-27 01:19 | 2026-03-24 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner; President and CEO | Pharmaceutical Preparations | SALE | $55.21 | 21,120 | $1,166,105 | 52,200 | -28.8% |
| 2026-03-27 00:36 | 2026-03-26 | CNTA | Centessa Pharmaceuticals plc | Weinhoff Gregory M | Officer; Chief Business Officer | Pharmaceutical Preparations | OPT+S | $30.00 | 23,998 | $719,940 | 65,925 | -26.7% |
| 2026-03-27 00:04 | 2026-03-25 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | Officer; See Remarks | Biological Products, (No Diagnostic Substances) | OPT+S | $95.56 | 37,450 | $3,578,819 | 54,400 | -40.8% |
| 2026-03-27 00:05 | 2026-03-24 | BCDA | BioCardia, Inc. | Altman Peter | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | BUY | $1.23 | 900 | $1,110 | 274,766 | +0.3% |
| 2026-03-27 00:00 | 2026-03-25 | ACAD | ACADIA PHARMACEUTICALS INC | Schneyer Mark C. | Officer; EVP, CHIEF FINANCIAL OFFICER | Pharmaceutical Preparations | OPT+S | $21.55 | 7,385 | $159,136 | 60,269 | -10.9% |
| 2026-03-27 00:00 | 2026-03-25 | ACAD | ACADIA PHARMACEUTICALS INC | Kihara James | Officer; PRINCIPAL ACCOUNTING OFFICER | Pharmaceutical Preparations | OPT+S | $21.57 | 1,942 | $41,895 | 26,885 | -6.7% |
| 2026-03-27 00:00 | 2026-03-25 | ACAD | ACADIA PHARMACEUTICALS INC | Rhodes Jennifer J | Officer; EVP, CHIEF LEGAL OFFICER, SEC | Pharmaceutical Preparations | OPT+S | $21.47 | 3,844 | $82,531 | 11,280 | -25.4% |
| 2026-03-27 00:00 | 2026-03-25 | ACAD | ACADIA PHARMACEUTICALS INC | Thompson Elizabeth H.Z. | Officer; EVP, Head of Research & Dev | Pharmaceutical Preparations | OPT+S | $21.47 | 3,435 | $73,749 | 3,280 | -51.2% |
| 2026-03-27 00:00 | 2026-03-25 | ACAD | ACADIA PHARMACEUTICALS INC | Owen Adams Catherine | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | OPT+S | $21.47 | 11,641 | $249,932 | 14,803 | -44.0% |
| 2026-03-26 23:41 | 2026-03-24 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer; President and COO | Biological Products, (No Diagnostic Substances) | OPT+S | $14.03 | 57,180 | $802,235 | 468,892 | -10.9% |
| 2026-03-26 23:21 | 2026-03-25 | BCAX | Bicara Therapeutics Inc. | Raben David | Officer; Chief Medical Officer | Pharmaceutical Preparations | OPT+S | $18.95 | 5,500 | $104,229 | 55,286 | -9.0% |
| 2026-03-26 22:57 | 2026-03-24 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $5.41 | 20,082 | $108,632 | 2,460,000 | +0.8% |
| 2026-03-26 22:42 | 2026-03-25 | DFTX | Definium Therapeutics, Inc. | Barrow Robert | Director, Officer; Chief Executive Officer | Medicinal Chemicals & Botanical Products | SALE | $18.47 | 24,431 | $451,241 | 752,454 | -3.1% |
| 2026-03-26 22:42 | 2026-03-25 | DFTX | Definium Therapeutics, Inc. | Sullivan Mark | Officer; Chief Legal Officer | Medicinal Chemicals & Botanical Products | SALE | $18.47 | 10,702 | $197,666 | 271,079 | -3.8% |
| 2026-03-26 22:43 | 2026-03-25 | DFTX | Definium Therapeutics, Inc. | Karlin Daniel | Officer; Chief Medical Officer | Medicinal Chemicals & Botanical Products | SALE | $18.47 | 8,018 | $148,092 | 413,317 | -1.9% |
| 2026-03-26 22:00 | 2026-03-24 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Soteropoulos Paula | Director | Pharmaceutical Preparations | OPT+S | $78.05 | 27,594 | $2,153,712 | 0 | -100.0% |
| 2026-03-26 21:39 | 2026-03-24 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | Pharmaceutical Preparations | SALE | $5.56 | 17,909 | $99,506 | 532,091 | -3.3% |
| 2026-03-26 21:00 | 2026-03-24 | GNLX | GENELUX Corp | Zindrick Thomas | Officer; President and CEO | Pharmaceutical Preparations | SALE | $2.42 | 3,582 | $8,668 | 534,849 | -0.7% |
| 2026-03-26 21:00 | 2026-03-24 | GNLX | GENELUX Corp | Yu Yong | Officer; SVP, Clinical Development | Pharmaceutical Preparations | SALE | $2.42 | 906 | $2,193 | 144,938 | -0.6% |
| 2026-03-26 21:00 | 2026-03-24 | GNLX | GENELUX Corp | Cappello Joseph | Officer; Chief Technical Officer | Pharmaceutical Preparations | SALE | $2.42 | 906 | $2,193 | 155,154 | -0.6% |
| 2026-03-26 21:00 | 2026-03-24 | GNLX | GENELUX Corp | Smalling Ralph | Officer; Head of Regulatory | Pharmaceutical Preparations | SALE | $2.46 | 585 | $1,437 | 68,073 | -0.9% |
| 2026-03-26 20:34 | 2026-03-26 | UTHR | UNITED THERAPEUTICS Corp | Thompson Tommy G | Director | Pharmaceutical Preparations | OPT+S | $539.17 | 2,000 | $1,078,332 | 8,480 | -19.1% |
| 2026-03-26 20:34 | 2026-03-25 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $543.73 | 9,500 | $5,165,475 | 40,513 | -19.0% |
| 2026-03-26 20:41 | 2026-03-25 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Officer; Chief Development Officer | Pharmaceutical Preparations | SALE | $29.99 | 10,115 | $303,355 | 286,876 | -3.4% |
| 2026-03-26 20:30 | 2026-03-24 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $98.15 | 25,130 | $2,466,610 | 85,533 | -22.7% |
| 2026-03-25 23:55 | 2026-03-23 | IBO | IMPACT BIOMEDICAL INC. | Grady Jason | Director | Pharmaceutical Preparations | SALE | $0.65 | 50,000 | $32,505 | 250,182 | -16.7% |
| 2026-03-25 23:57 | 2026-03-13 | TLPH | TALPHERA, INC. | Angotti Vincent J. | Director, Officer; CHIEF EXECUTIVE OFFICER | Pharmaceutical Preparations | BUY | $0.59 | 213,310 | $125,000 | 800,705 | +36.3% |
| 2026-03-26 00:00 | 2026-03-23 | CYRX | Cryoport, Inc. | Sawicki Mark W | Officer; Chief Scientific Officer | Pharmaceutical Preparations | SALE | $8.18 | 1,341 | $10,969 | 102,356 | -1.3% |
| 2026-03-26 00:00 | 2026-03-23 | CYRX | Cryoport, Inc. | SHELTON JERRELL | Director, Officer; President, CEO | Pharmaceutical Preparations | OPT+S | $8.18 | 2,894 | $23,673 | 1,051,607 | -0.3% |
| 2026-03-26 00:01 | 2026-03-23 | CYRX | Cryoport, Inc. | STEFANOVICH ROBERT | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $8.18 | 1,094 | $8,949 | 279,277 | -0.4% |
| 2026-03-26 00:02 | 2026-03-23 | SRZN | Surrozen, Inc./DE | TCG Crossover GP II, LLC | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $24.72 | 121,881 | $3,012,764 | 736,547 | +19.8% |
| 2026-03-25 23:23 | 2026-03-24 | PTGX | Protagonist Therapeutics, Inc | PATEL DINESH V PH D | Director, Officer; President and CEO | Pharmaceutical Preparations | OPT+S | $101.00 | 54,700 | $5,524,700 | 524,938 | -9.4% |
| 2026-03-25 21:32 | 2026-03-24 | TPST | Tempest Therapeutics, Inc. | Angel Matthew | Director, Officer, 10% owner; CEO and President | Pharmaceutical Preparations | BUY | $2.16 | 231,482 | $500,001 | 231,482 | +100.0% |
| 2026-03-25 21:05 | 2026-03-23 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer; EVP & CFO | Pharmaceutical Preparations | SALE | $45.53 | 34,791 | $1,583,989 | 43,886 | -44.2% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.